I-124 evuzamitide PET/CT shows high sensitivity in cardiac amyloidosis detection

Results from the phase 3 REVEAL study indicate that I-124 evuzamitide PET/CT scans are highly sensitive and specific for the detection of cardiac amyloidosis. The findings were presented by Mathew Maurer, MD, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona.

Dr. Maurer, a professor of cardiology at Columbia University Irving Medical Center, noted that this technology could provide a more sensitive and specific method for diagnosing amyloidosis compared to currently available imaging. Early diagnosis is critical, as it allows for drug therapy when it is most effective, before the patient develops advanced cardiac amyloid.

The REVEAL study was a multicenter, open-label trial involving patients suspected of having cardiac amyloidosis. Participants received a single intravenous dose of I-124 evuzamitide, followed by oral potassium iodide for three days. The study's primary endpoint focused on the sensitivity and specificity of the PET/CT images.